logo-loader
viewOncimmune

Oncimmune teams up with one of the world’s largest pharmaceuticals companies to screen for lung cancer

The latest agreement is one of a series of deals inked in the last two months that showed  the “full breadth” of the firm’s commercial offering, said chief executive Adam Hill

Oncimmune -

Oncimmune Holdings PLC (LON:ONC) revealed that it has signed a ‘foothill contract’ with one of the world’s largest pharmaceuticals companies, which will evaluate the potential of Oncimmune’s technology to screen for lung cancer in at-risk patients.

This initial tie-up could be the “first step” towards a long-term partnership with the unnamed partner that would see the widespread availability of the EarlyCDT Lung test, investors were told.

The latest agreement is one of a series of deals inked in the last two months that showed the “full breadth” of the firm’s commercial offering, said chief executive Adam Hill.

“Our three-year strategy, announced in late 2018, centred on identifying and capitalising upon the wide range of opportunities presented by Oncimmune's proprietary autoantibody-based platform,” he explained in a statement.

“We firmly believe that the momentum we are building validates our strategy and underpins the commercial potential of our business.”

Quick facts: Oncimmune

Price: 149.5 GBX

AIM:ONC
Market: AIM
Market Cap: £94.99 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Oncimmune CEO says they're seeing 'significant interest' in its EarlyCDT...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business while the pipeline of contracts within the ImmunoINSIGHTS services business is building. In a trading update covering the...

on 5/6/20

2 min read